论文部分内容阅读
[目的]观察盐酸埃克替尼治疗复治晚期非小细胞肺癌(NSCLC)患者的疗效及安全性。[方法]对215例复治晚期NSCLC患者应用埃克替尼125mg/次,一日3次,直到疾病进展或者出现不可耐受的不良反应。[结果]全组患者达到完全缓解(CR)2例(0.9%),部分缓解(PR)75例(34.9%),疾病稳定(SD)67例(31.2%),疾病进展(PD)71例(33.0%)。客观缓解率(RR)35.8%,疾病控制率(DCR)67.0%。女性、腺癌、ECOG PS评分≤1、非吸烟及EGFR基因突变阳性患者RR显著性高于男性、非腺癌、ECOG PS评分≥2、吸烟及EGFR基因突变未知及野生型患者(P<0.05)。女性、ECOG PS评分≤1及非吸烟患者DCR显著性高于男性、ECOG PS评分≥2及吸烟患者(P<0.05)。中位无进展时间(m PFS)为6.8个月(95%CI:5.9~7.7个月),中位生存时间(m OS)为15.5个月(95%CI:14.0~16.9个月)。女性、非吸烟、腺癌、ECOG PS评分≤1及EGFR基因突变阳性患者m PFS明显优于男性、吸烟、非腺癌、ECOG PS评分≥2及EGFR基因突变未知及野生型患者(P<0.05)。主要不良反应多为Ⅰ~Ⅱ度的皮疹(39.5%)和腹泻(27.4%),大部分患者均可耐受。[结论 ]埃克替尼用于复治NSCLC患者尤其是EGFR基因突变阳性腺癌患者具有较好的疗效,不良反应多可耐受。
[Objective] To observe the efficacy and safety of imatinib hydrochloride in the treatment of advanced non-small cell lung cancer (NSCLC). [Method] Icitinib 125 mg / time was administered to 215 patients with advanced NSCLC, three times a day until disease progression or intolerable adverse reactions. [Results] All patients achieved complete remission (CR) in 2 patients (0.9%), partial response (PR) in 75 patients (34.9%), stable disease (SD) in 67 patients (31.2%) and disease progression (PD) in 71 patients (33.0%). The objective response rate (RR) 35.8%, disease control rate (DCR) 67.0%. In women with adenocarcinoma, ECOG PS score≤1, RR of non-smoking and EGFR gene mutation was significantly higher than that of male, non-adenocarcinoma, ECOG PS score≥2, smoking and EGFR gene mutation were unknown and wild type patients (P <0.05 ). In women, ECOG PS scores ≤1 and non-smoking DCR were significantly higher than men, ECOG PS score ≥2 and smoking patients (P <0.05). Median progression-free time (m PFS) was 6.8 months (95% CI: 5.9 to 7.7 months) and median survival time (m OS) was 15.5 months (95% CI: 14.0 to 16.9 months). Smoking, non-adenocarcinoma, ECOG PS score≥2 and EGFR gene mutation were not significantly different between the female and non-smoking, adenocarcinoma patients with ECOG PS score≤1 and those with EGFR gene mutation positive (P <0.05) ). The main side effects were grade Ⅰ ~ Ⅱ rash (39.5%) and diarrhea (27.4%). Most patients were tolerated. [Conclusion] The efficacy of icitin in rehabilitating NSCLC patients, especially patients with EGFR gene mutation positive adenocarcinoma, has good curative effect and tolerable adverse reactions.